期刊
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
卷 31, 期 3, 页码 364-372出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2017.09.012
关键词
Systemic lupus erythematosus; Cardiovascular disease; Atherosclerosis; Lipids; Risk stratification; Autoantibodies; Invariant natural killer T cells
类别
资金
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
Cardiovascular disease (CVD), comprising coronary heart disease and stroke, is one of the most important causes of death in patients with systemic lupus erythematosus (SLE). The risks of developing both clinical CVD and sub-clinical atherosclerosis are increased in patients with SLE. This increase is not fully explained by traditional cardiovascular risk factors such as smoking, hypertension and elevated cholesterol, and it is believed that immune dysfunction also contributes to CVD risk in SLE. In particular, recent studies have shown that abnormalities in both serum lipid profile and the autoantibody and T lymphocyte response to lipids may play a role in development of atherosclerosis. The standard CVD risk calculation algorithms based on traditional risk factors underestimate the risk of developing CVD in patients with SLE. Thus, novel algorithms incorporating new biomarkers such as pro-inflammatory high-density lipoprotein and use of imaging techniques such as carotid ultrasound scanning may become increasingly valuable. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据